33
Participants
Start Date
November 25, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
December 31, 2027
R2P -> RP
"Induction(R2P) 21 days per cycles, 6 cycles~* NB02 : 60mg BID PO, Day 1-21~* Rituximab 375mg/m2 DAY IV Day 1, 8, 15 at 1st cycle; D1 at 2nd to 6th cycles~* Lenalidomide : 20mg QD PO, Day 1-14~Maintenance(RP) 21 days per cycles, until Progression~* NB02 : 60mg BID PO, Day 1-21~* Lenalidomide : 20mg QD PO, Day 1-14"
NOT_YET_RECRUITING
Kosin University Gospel Hospital, Busan
NOT_YET_RECRUITING
Chonnam National University Hwasun Hospital, Hwasun
NOT_YET_RECRUITING
Korea National Cancer Center, Ilsan
NOT_YET_RECRUITING
Seoul National University Bundang Hospital, Seongnam
NOT_YET_RECRUITING
Asan Medical Center, Seoul
NOT_YET_RECRUITING
Catholic univ of Yeouido St Mary's Hospital, Seoul
NOT_YET_RECRUITING
Korea University Anam Hospital, Seoul
NOT_YET_RECRUITING
Samsung Medical Center, Seoul
RECRUITING
Seoul National University Hospital, Seoul
NOT_YET_RECRUITING
Ulsan University Hospital, Ulsan
Lead Sponsor
NOBO Medicine
INDUSTRY